The effects of moclobemide on the pharmacokinetics of the 5-HT(1B/1D) agonist rizatriptan in healthy volunteers

AIMS: The new 5-HT(1B/1D) agonist rizatriptan (MK-0462) has recently been registered for the treatment of migraine. Its primary route of metabolism is via monoamine oxidase-A (MAO-A). Antidepressants such as the MAO-A inhibitor moclobemide may be used in patients with chronic headache syndromes. Hen...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: van Haarst, A D, van Gerven, J M A, Cohen, A F, De Smet, M, Sterrett, A, Birk, K L, Fisher, A L, De Puy, M E, Goldberg, M R, Musson, D G
Formato: Artigo
Lenguaje:Inglês
Publicado: Blackwell Science Inc 1999
Materias:
Drug Interactions
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2014288/
https://ncbi.nlm.nih.gov/pubmed/10417495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.1999.00011.x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares